Ajanta Pharma Guwahati Facility To Be Ready By March
Mumbai: Drug maker Ajanta Pharma said its new formulations facility at Guwahati will be commercialised before March 2017 and the Dahej manufacturing facility, mainly dedicated for developed markets, will be operational in next financial year.
"Our new formulations facility being set up at Guwahati with a capex of over Rs 300 crore to cater to India and emerging markets will be commercialised before March 2017, which will enable us to build our strength in manufacturing and get more tax efficient," the Mumbai-based company said in its annual report.
The facility will produce tablets, capsules, creams/ointments and sterile ophthalmic liquids.
"The company is also adding manufacturing capacities for different markets. The Dahej manufacturing facility mainly dedicated for developed markets, will be operational by FY 18," Ajanta Pharma managing director Yogesh Agrawal said in the annual report.
With substantial investments of Rs 106 crore in R&D in 2015-16, use of latest platform technologies and developing niche and complex formulations, the company is confident of reinforcing its exclusive positioning in the markets it operates in.
The company has a strong presence in the branded generics space in more than 30 emerging countries across India, Africa, CIS, Middle East and South East Asia, generics in developed markets of the US, and institutional sales.
The company has stepped up its presence in the US market with a select product portfolio.
It has 26 abbreviated new drug applications (ANDAs), out of which we received 8 final approvals and two tentative approvals. "We are awaiting for approvals of 16 ANDAs and plans to file 8-12 ANDAs every year for every year with the US FDA going forward," Mr Agrawal said.
The company plans to remain focused on few high growth specialty therapeutic segments in India and building leadership in cardiology, dermatology, ophthalmology and pain management.
In the emerging markets, its vision is to provide differentiated products, customized to suit individual marketplace with a bouquet of 1400 plus product registration in hand and another equal number under approval, the company said.Â
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
